Siamab’s Antibody-drug Conjugates for Ovarian Cancer Seen to Succeed in Animal Models
Siamab Therapeutics’ preclinical work with anti-STn antibody-drug conjugates is moving forward, and in animal models — including primates — it showed the conjugates could safely and effectively treat ovarian cancer resistant to chemotherapy. Read more >>